Metacrine, Inc. Common Stock (MTCR)

MTCR was delisted on the 8th of February, 2023.

• Market cap: $21.1M
• Sector: Healthcare
• Industry: Drug Manufacturers - General

About: Metacrine Inc is a clinical-stage biopharmaceutical company focused on discovering and developing differentiated therapies for patients with liver and gastrointestinal diseases. Its program targets the farnesoid X receptor, or FXR, which is central to modulating liver and GI diseases. Its FXR product candidates include MET409 and MET642.

Employees: 10